Replies to post #219962 on Biotech Values

[GrthzGd]

Kudos if you bought ACAD on its short-induced dip IMO.

[IanFromSI]

IR's response was far too polite.

I'd have written something along the lines of:

Roddy,

You're a blithering f*&^ing idiot.

It was only approved in 2016.
Sales effectively started in 2017.


The drug is a huge success in treating pts.
Doctors, patients and caregivers have seen this.
Its usage is growing rapidly.

Of course, there are more AEs reported given the rapid growth in usage and pts treated and their life expectancy.

And there's no safer option for achieving the improved quality of life delivered by Nuplazid.